The trials delivered some success [...] but when high-doses of the drug were linked with increased rates of cancer in animals, GSK decided to scrap further development of the drug for humans.
Is there some indication of a new approach without the increased cancer risk? Not seeing it from the Verge article, though I could have missed something.
The trials delivered some success [...] but when high-doses of the drug were linked with increased rates of cancer in animals, GSK decided to scrap further development of the drug for humans.
Is there some indication of a new approach without the increased cancer risk? Not seeing it from the Verge article, though I could have missed something.